Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Eric P. Winer(University of Vermont), Giuseppe Curigliano(European Institute of Oncology), David Cameron(Corewell Health), Sherene Loi(The University of Melbourne), Carey K. Anders(Duke University), Dennis J. Slamon(University of California, Los Angeles), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Maria Corinna Palanca-Wessels(Unknown), Sofía Braga(Hospital Prof. Dr. Fernando Fonseca), Mark D. Pegram(Stanford University), François P. Duhoux(Cliniques Universitaires Saint-Luc), Ian E. Krop(Yale Cancer Center), Richard Greil(Paracelsus Medical University), Philippe L. Bédard(Princess Margaret Cancer Centre), Thomas Bachelot(Centre Léon Bérard), Shlomit Strulov Shachar(Tel Aviv Sourasky Medical Center), Nancy U. Lin(Dana-Farber Cancer Institute), Lisa A. Carey(University of North Carolina at Chapel Hill), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Wentao Feng(Seagen (United States)), Alicia Okines(Royal Marsden NHS Foundation Trust), Karen A. Gelmon(University of British Columbia), Sara A. Hurvitz(University of Washington), Erik Jakobsen(Aarhus University Hospital), Vandana G. Abramson(Vanderbilt University), Sibylle Loibl(Goethe University Frankfurt), Volkmar Müller(Universität Hamburg), Elisavet Paplomata(Cancer Research UK), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Luke Walker(Cancer Research UK), Erika Hamilton(Sarah Cannon)
Cited by 1,334
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k